Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$161.97 USD

161.97
575,208

+1.87 (1.17%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 6% (15 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Strength Seen in Oak Street Health, Inc. (OSH): Can Its 29.7% Jump Turn into More Strength?

Oak Street Health, Inc. (OSH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

U.S. Physical Therapy (USPH) Soars 3.6%: Is Further Upside Left in the Stock?

U.S. Physical Therapy (USPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Here's Why You Should Retain DaVita (DVA) Stock for Now

Investors remain optimistic about DaVita (DVA) due to the strength in its DaVita Kidney Care.

Is the Options Market Predicting a Spike in DaVita (DVA) Stock?

Investors need to pay close attention to DaVita (DVA) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in DaVita (DVA) Stock?

Investors need to pay close attention to DaVita (DVA) stock based on the movements in the options market lately.

DaVita (DVA) Q3 Earnings Lag Estimates, 2022 EPS View Cut

DaVita's (DVA) Q3 performance gets a boost from strength in both its segments.

DaVita HealthCare (DVA) Q3 Earnings and Revenues Lag Estimates

DaVita HealthCare (DVA) delivered earnings and revenue surprises of -12.12% and 1.08%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

DaVita (DVA) to Report Q3 Earnings: What's in the Offing?

High labor costs, along with inflationary pressures, are likely to have weighed on DaVita's (DVA) third quarter's top line.

DaVita HealthCare (DVA) Up 0.7% Since Last Earnings Report: Can It Continue?

DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

DaVita (DVA) Beats on Q2 Earnings, Reiterates FY22 EPS View

DaVita (DVA) records an overall solid Q2 performance owing to strength in its Other segment's revenues and uptick in total U.S. dialysis treatments.

DaVita HealthCare (DVA) Tops Q2 Earnings Estimates

DaVita HealthCare (DVA) delivered earnings and revenue surprises of 9% and 0.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

DaVita (DVA) to Report Q2 Earnings: What's in the Offing?

Supply constraints, along with inflationary pressures, is likely to have weighed on DaVita's (DVA) second quarter's top line.

3 Reasons to Retain DaVita (DVA) Stock in Your Portfolio

Investors remain optimistic about DaVita (DVA) due to strength in its DaVita Kidney Care.

DaVita HealthCare (DVA) Surges 6%: Is This an Indication of Further Gains?

DaVita HealthCare (DVA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Here's Why You Should Hold on to DaVita (DVA) Stock For Now

Investors remain optimistic about DaVita (DVA) due to strength in its DaVita Kidney Care and impressive overseas growth.

Trina Mukherjee headshot

3 Stocks to Watch From a Buoyant Outpatient Home Health Industry

Despite the COVID-19 pandemic-induced challenges, rising dependence on telehealth and AI's dominant role are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, RDNT and USPH are well-poised to gain from the prospects.

Medtronic's (MDT) New JV With DaVita to Expand Renal Care Line

NewCo is expected to operate successfully, leveraging Medtronic's (MDT) capabilities as a healthcare technology leader and DaVita's deep expertise as a comprehensive kidney care provider.

Reasons to Retain DaVita (DVA) Stock in Your Portfolio For Now

Investors remain optimistic about DaVita (DVA) due to strength in its DaVita Kidney Care and impressive overseas growth.

DaVita (DVA) Misses on Q1 Earnings, Reiterates FY22 EPS View

Despite strength in dialysis patient service revenues, DaVita (DVA) records an overall soft Q1 performance.

DaVita HealthCare (DVA) Q1 Earnings and Revenues Lag Estimates

DaVita HealthCare (DVA) delivered earnings and revenue surprises of -12.97% and 2.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

DaVita (DVA) to Report Q1 Earnings: What's in the Offing?

Supply shortage along with pandemic-led incremental mortality rate is likely to have weighed on DaVita's (DVA) first-quarter top line.

LHC Group (LHCG) Ties Up to Improve Home Health Services

LHC Group's (LHCG) latest joint venture with Archbold Medical Center to enhance home health services in Thomasville and across South Georgia.

Here's Why You Should Hold on to DaVita (DVA) Stock Now

DaVita (DVA) continues to gain traction from its strong international presence and solid DaVita Kidney Care business. However, integration risks are a woe.

Is DaVita (DVA) a Suitable Value Investor Stock Now?

Let's see if DaVita (DVA) stock is a good choice for value-oriented investors right now from multiple angles.

DaVita's (DVA) Q4 Earnings Surpass Estimates, Margins Up

DaVita's (DVA) strength in dialysis patient service revenues drives its Q4 top line.